<DOC>
	<DOC>NCT01040156</DOC>
	<brief_summary>Pediatric patients are at high risk to acquire mycotic infections following allogeneic bone marrow transplantation. In the present retrospective analysis we assess the safety and efficacy of different regimens in antimycotic prophylaxis.</brief_summary>
	<brief_title>Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Pediatric patients under the age of 18 years Pediatric patients after HSCT treated with caspofungin Pediatric patients after HSCT treated with liposomal amphotericin Pediatric patients with uncontrolled hematological malignancies Pediatric patients with IFI at start of HSCT</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>